Lacosamide
| Clinical data | |
|---|---|
| Trade names | Vimpat |
| Other names | (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a609028 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | High |
| Elimination half-life | 13 hours |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.112.805 |
| Chemical and physical data | |
| Formula | C13H18N2O3 |
| Molar mass | 250.298 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of focal-onset seizures and primary generalized tonic–clonic seizures. It is used by mouth or intravenously.
It is available as a generic medication.